Rituximab for troublesome cases of childhood nephrotic syndrome

来源 :World Journal of Clinical Pediatrics | 被引量 : 0次 | 上传用户:DK7531672
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Nephrotic syndrome(NS) is the most common glomerular disease of childhood. Steroid-dependent and steroid-resistant nephrotic syndrome present challenges in their pharmaceutical management; patients may need several immunosuppressive medication for optimum control, each of which medication has its own safety profile. Rituximab(RTX) is a monoclonal antibody that targets B cells and has been used successfully for management of lymphoma and rheumatoid arthritis. Recent clinical studies showed that rituximab may be an efficacious and safe alternative for the treatment of complicated nephrotic syndrome. In this review article, we aim to review the efficacy and safety of RTX therapy in nephrotic syndrome. We reviewed the literature pertaining to this topic by searching for relevant studies on Pub Med and Medline using specific keywords. The initial search yielded 452 articles. These articles were then examined to ensure their relevance to the topic of research. We focused on multicenter randomized controlled trials with relatively large numbers of patients. A total of 29 articles were finally identified and will be summarized in this review. The majority of clinical studies of RTX in complicated pediatric NS showed that rituximab is effective in approximately 80% of patients with steroid-dependent NS, as it decreases the number of relapses and steroid dosage. However, RTX is less effective at achieving remission in steroid-resistant NS. RTX use was generally safe, and most side effects were transient and infusion-related. More randomized, double-blinded clinical studies are needed to assess the role of RTX in children with nephrotic syndrome. Nephrotic syndrome (NS) is the most common glomerular disease of childhood. Steroid-dependent and steroid-resistant nephrotic syndrome present challenges in their pharmaceutical management; patients may need several immunosuppressive drugs for optimum control, each of which has its own safety profile. Rituximab (RTX) is a monoclonal antibody that targets B cells and has been used successfully for management of lymphoma and rheumatoid arthritis. Recent clinical studies showed that rituximab may be an efficacious and safe alternative for the treatment of complicated nephrotic syndrome. , we aim to review the efficacy and safety of RTX therapy in nephrotic syndrome. We reviewed the literature pertaining to this topic by searching for relevant studies on Pub Med and Medline using specific keywords. The initial search generated 452 articles. These articles were then examined to ensure their relevance to the topic of research. We focused on multicenter rando The majority of clinical studies of RTX in complicated pediatric NS showed that rituximab is effective in about 80% of patients with steroid -dependent NS, as it reduces the number of relapses and steroid dosage. However, RTX is less effective at achieving remission in steroid-resistant NS. RTX use was generally safe, and most side effects were transient and infusion-related. More randomized, double-blinded clinical studies are needed to assess the role of RTX in children with nephrotic syndrome.
其他文献
请下载后查看,本文暂不支持在线获取查看简介。 Please download to view, this article does not support online access to view profile.
重症类风湿性关节炎(RA)可伴有全身性损害而危及生命,目前有关RA关节外表现的本质研究尚少,对IgA类风湿因子(RF)在RA关节外表现中的意义仍存在争议。本研究测定了RA病人的IgARF,评价它与RA临床特
利用简单的方法和较少的胶体乳液,在没有任何特殊设备的情况下制备出了二维和三维的有序阵列。通过控制胶体乳液浓度获得了层数可控的胶体晶体有序阵列。通过使用现有成膜模
目的筛选太白洋参中化学成分提取的最佳工艺条件。方法采用HPLC法,以太白洋参中桃叶珊瑚苷相对含量为评判指标,通过正交试验设计,考察乙醇浓度,提取时间、提取次数、温度等因
Sprague-Dawley雄性大鼠腹腔内注射STZ制造糖尿病(DM)动物模型.依据表现、尿糖、血糖及糖化血红蛋白综合诊断DM.观察Ⅰ组(6周)、Ⅱ组(8周)及Ⅲ组(12周)中DM组、NDM组(空白对
为了建立一种花生油掺伪快速检测方法 ,以我国居民常见的花生油品种和其他食用油为原料,通过比较其傅里叶变换红外光谱(FTIR),确定花生油特征光谱区域。配制成一定混合比例的
胎儿宫内发育迟缓的发病率和死亡率均较高 ,在各种引起胎儿发病和死亡的病理因素中居第二位 ,仅次于早产[1,2 ] 。胎儿宫内发育迟缓 (intrauter inegrowthretardation ,IUGR)